The product, available in 200 mg, 400 mg, 600 mg, and 800 mg strengths, is the generic equivalent of Sumitomo Pharma ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market.

With this launch, Lupin's FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to Lupin’s FY26 earnings.

One such question comes out of the beginning of the much-loved third installment, Harry Potter and the Prisoner of Azkaban, when the trio finds Remus Lupin (David Thewlis) asleep on the Hogwarts ...

Tolvaptan slows down the deterioration of kidney function in adults who are at risk of rapidly progressing autosomal dominant ...

Some estimates had projected Myrbetriq to contribute close to $30 million each to the quarterly sales of both the pharma companies, a note by Equirus said, suggesting a possible financial penalty as ...

According to reports, the executive order signed by Trump directs the US Food and Drug Administration (USFDA) to streamline ...

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

Lupin Digital Health marked the company’s foray into the fast-growing digital therapeutics space. Its Lyfe platform focuses on real-time monitoring of patients and offers interventions for cardiac ...

Zee Business editor, Anil Singhvi breaks down implications for Indian pharma and highlights key stocks to watch ...

Australian regenerative food and agriculture company Wide Open Agriculture (WOA) has signed an offtake and distribution ...